替格瑞洛与氯吡格雷在韩国急性冠脉综合征拟行侵入性治疗患者中的临床显著出血比较:一项随机临床试验
该多中心随机试验纳入800例拟行侵入性治疗的韩国急性冠脉综合征患者,1:1分配至替格瑞洛或氯吡格雷。12个月时替格瑞洛组临床显著出血发生率显著高于氯吡格雷组(11.7% vs 5.3%;HR 2.26;95%CI 1.34-3.79;P=0.002),主要出血和致命出血亦更高;心血管死亡、心肌梗死或卒中发生率无显著差异(9.2% vs 5.8%;HR 1.62;95%CI 0.96-2.74;P=0.07)。
要点
- 韩国ACS拟行侵入性治疗患者中,标准剂量替格瑞洛较氯吡格雷显著增加临床显著出血风险。
- 替格瑞洛组主要出血(7.5% vs 4.1%,P=0.04)和致命出血(1% vs 0%,P=0.04)均更高。
- 缺血事件(心血管死亡、心梗或卒中)两组无显著差异,但试验效能不足以得出有效性结论。
核心结论
- 在拟行早期侵入性治疗的韩国ACS患者中,标准剂量替格瑞洛与氯吡格雷相比与更高的临床显著出血发生率相关。
- 缺血事件发生率在替格瑞洛组数值上更高,但应谨慎解读,因本试验对有效性结论的把握度不足。
研究设计与样本
- 多中心随机临床试验,纳入800例因急性冠脉综合征(伴或不伴ST段抬高)住院且拟行侵入性治疗的韩国患者。
- 患者按1:1随机接受替格瑞洛(负荷180 mg,此后90 mg每日两次)或氯吡格雷(负荷600 mg,此后75 mg每日一次)。
- 主要安全终点为12个月时临床显著出血,即PLATO标准定义的主要出血或次要出血的复合终点。
主要发现
- 12个月时临床显著出血发生率替格瑞洛组为11.7%(45/400),氯吡格雷组为5.3%(21/400);HR 2.26;95%CI 1.34-3.79;P=0.002。
- 主要出血发生率替格瑞洛组7.5%(29/400),氯吡格雷组4.1%(16/400),P=0.04。
- 致命出血发生率替格瑞洛组1%(4/400),氯吡格雷组0%,P=0.04。
- 心血管死亡、心肌梗死或卒中发生率替格瑞洛组9.2%(36/400),氯吡格雷组5.8%(23/400);HR 1.62;95%CI 0.96-2.74;P=0.07。
- 采用多种分析方法和多个亚组中,总体安全性和有效性结果相似。
关键数值与推荐
- 主要安全终点为12个月时PLATO标准定义的临床显著出血(主要出血或次要出血复合终点)。
- 替格瑞洛用法:负荷180 mg,此后90 mg每日两次;氯吡格雷用法:负荷600 mg,此后75 mg每日一次。
临床怎么用
- 对于拟行侵入性治疗的韩国ACS患者,选择替格瑞洛时需充分评估出血风险,权衡其较氯吡格雷更高的临床显著出血、主要出血及致命出血风险。
- 本试验未显示替格瑞洛在缺血事件上的显著获益,且效能不足,临床决策应结合患者个体出血与缺血风险综合判断。
局限性
- 本试验对有效性结论的把握度不足,缺血事件数值差异应谨慎解读。
- 研究人群为韩国ACS患者,结果外推至其他东亚人群或其他地区人群需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Owing to the differential propensity for bleeding and ischemic events with response to antiplatelet therapy, the safety and effectiveness of potent P2Y12 inhibitor ticagrelor in East Asian populations remain uncertain. METHODS: In this multicenter trial, 800 Korean patients hospitalized for acute coronary syndromes with or without ST elevation and intended for invasive management were randomly assigned to receive, in a 1:1 ratio, ticagrelor (180 mg loading dose, 90 mg twice daily thereafter) or clopidogrel (600 mg loading dose, 75 mg daily thereafter). The primary safety outcome was clinically significant bleeding (a composite of major bleeding or minor bleeding according to PLATO (Platelet Inhibition and Patient Outcomes) criteria at 12 months. RESULTS: At 12 months, the incidence of clinically significant bleeding was significantly higher in the ticagrelor group than in the clopidogrel group (11.7% [45/400] vs 5.3% [21/400]; hazard ratio [HR], 2.26; 95% confidence interval [CI], 1.34 to 3.79; P=0.002). The incidences of major bleeding (7.5% [29/400] vs 4.1% [16/400], P=0.04) and fatal bleeding (1% [4/400] vs 0%, P=0.04) were also higher in the ticagrelor group. The incidence of death from cardiovascular causes, myocardial infarction, or stroke was not significantly different between the ticagrelor group and the clopidogrel group (9.2% [36/400] vs 5.8% [23/400]; HR, 1.62; 95% CI, 0.96 to 2.74; P=0.07). Overall safety and effectiveness findings were similar with the use of several different analytic methods and in multiple subgroups. CONCLUSIONS: In Korean acute coronary syndrome patients intended to receive early invasive management, standard-dose ticagrelor as compared with clopidogrel was associated with a higher incidence of clinically significant bleeding. The numerically higher incidence of ischemic events should be interpreted with caution, given the present trial was underpowered to draw any conclusion regarding efficacy. CLINICAL TRIAL REGISTRATION: URL: https://www.clinicaltrials.gov. Unique identifier: NCT02094963.
引用
- Park DW, Kwon O, Jang JS, et al. Clinically Significant Bleeding With Ticagrelor Versus Clopidogrel in Korean Patients With Acute Coronary Syndromes Intended for Invasive Management: A Randomized Clinical Trial. Circulation. 2019. PMID: 31553203. doi:10.1161/CIRCULATIONAHA.119.041766
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。